242 related articles for article (PubMed ID: 20017601)
1. Pharmaceutical development of microbicide drug products.
Friend DR
Pharm Dev Technol; 2010 Dec; 15(6):562-81. PubMed ID: 20017601
[TBL] [Abstract][Full Text] [Related]
2. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines.
Whaley KJ; Hanes J; Shattock R; Cone RA; Friend DR
Antiviral Res; 2010 Dec; 88 Suppl 1():S55-66. PubMed ID: 21109069
[TBL] [Abstract][Full Text] [Related]
3. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets.
Garg S; Goldman D; Krumme M; Rohan LC; Smoot S; Friend DR
Antiviral Res; 2010 Dec; 88 Suppl 1():S19-29. PubMed ID: 21109064
[TBL] [Abstract][Full Text] [Related]
4. Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: Development of dual-protection technologies.
Friend DR; Doncel GF
Antiviral Res; 2010 Dec; 88 Suppl 1():S47-54. PubMed ID: 21109068
[TBL] [Abstract][Full Text] [Related]
5. Advances in microbicide vaginal rings.
Malcolm RK; Edwards KL; Kiser P; Romano J; Smith TJ
Antiviral Res; 2010 Dec; 88 Suppl 1():S30-9. PubMed ID: 21109066
[TBL] [Abstract][Full Text] [Related]
6. Microbicide delivery: formulation technologies and strategies.
Romano J; Malcolm RK; Garg S; Rohan LC; Kaptur PE
Curr Opin HIV AIDS; 2008 Sep; 3(5):558-66. PubMed ID: 19373022
[TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
8. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned.
Friend DR; Kiser PF
Antiviral Res; 2013 Sep; 99(3):391-400. PubMed ID: 23845918
[TBL] [Abstract][Full Text] [Related]
9. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide.
Woolfson AD; Malcolm RK; Morrow RJ; Toner CF; McCullagh SD
Int J Pharm; 2006 Nov; 325(1-2):82-9. PubMed ID: 16884869
[TBL] [Abstract][Full Text] [Related]
10. Should microbicides be controlled by women or by physicians?
Piret J; Bergeron MG
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e14-7. PubMed ID: 20932483
[TBL] [Abstract][Full Text] [Related]
11. Microbicide dosage forms.
Rohan LC; Devlin B; Yang H
Curr Top Microbiol Immunol; 2014; 383():27-54. PubMed ID: 24220751
[TBL] [Abstract][Full Text] [Related]
12. Sustained release of microbicides by newly engineered vaginal rings.
Saxena BB; Han YA; Fu D; Rathnam P; Singh M; Laurence J; Lerner S
AIDS; 2009 May; 23(8):917-22. PubMed ID: 19381077
[TBL] [Abstract][Full Text] [Related]
13. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?
Martinez J; Coplan P; Wainberg MA
Antiviral Res; 2006 Sep; 71(2-3):343-50. PubMed ID: 16787667
[TBL] [Abstract][Full Text] [Related]
14. Electrospun fibers for vaginal anti-HIV drug delivery.
Blakney AK; Ball C; Krogstad EA; Woodrow KA
Antiviral Res; 2013 Dec; 100 Suppl():S9-16. PubMed ID: 24188701
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting sexual transmission of HIV-1 infection.
Shattock RJ; Moore JP
Nat Rev Microbiol; 2003 Oct; 1(1):25-34. PubMed ID: 15040177
[TBL] [Abstract][Full Text] [Related]
16. Future strategies in microbicide development.
Rosenberg ZF; Devlin B
Best Pract Res Clin Obstet Gynaecol; 2012 Aug; 26(4):503-13. PubMed ID: 22406260
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-based vaginal drug delivery systems for HIV prevention.
Mallipeddi R; Rohan LC
Expert Opin Drug Deliv; 2010 Jan; 7(1):37-48. PubMed ID: 20017659
[TBL] [Abstract][Full Text] [Related]
18. Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.
Notario-Pérez F; Ruiz-Caro R; Veiga-Ochoa MD
Drug Des Devel Ther; 2017; 11():1767-1787. PubMed ID: 28670111
[TBL] [Abstract][Full Text] [Related]
19. Nano-microbicides: challenges in drug delivery, patient ethics and intellectual property in the war against HIV/AIDS.
du Toit LC; Pillay V; Choonara YE
Adv Drug Deliv Rev; 2010 Mar; 62(4-5):532-46. PubMed ID: 19922751
[TBL] [Abstract][Full Text] [Related]
20. Current status of topical antiretroviral chemoprophylaxis.
Van Damme L; Szpir M
Curr Opin HIV AIDS; 2012 Nov; 7(6):520-5. PubMed ID: 22918449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
